Evidence-based articles, treatment guides, and the latest news in addiction recovery and mental health.
New data presented at ASAM 2026 shows extended-release buprenorphine (Sublocade) associated with lowest overdose rates among medication options and supports remission as meaningful treatment endpoint.
Utah joins $773.7 million national settlement with Albertsons Companies, directing funds to opioid abatement programs for treatment, recovery services, and prevention efforts.
FDA awards priority review vouchers to Compass Pathways, Usona Institute, and Transcend Therapeutics for psilocybin and methylone therapies targeting treatment-resistant depression and PTSD.
State regulations force daily clinic visits and limit take-home doses, making medication-assisted treatment more burdensome than federal standards require.
New research published in JAMA shows the 988 suicide crisis hotline is associated with significant reductions in suicide deaths among young people, with states showing highest call volume experiencing the greatest declines.
New Mexico becomes testing ground for SAMHSA-vetted digital recovery platform with dedicated teen version, offering 24/7 peer support and crisis intervention through smartphones.
New Child Trends analysis shows youth overdose deaths dropped 37% since 2023, with rates now lower than before the pandemic despite fentanyl's continued spread.
Mayor Brandon Scott unveils first annual report and public dashboard tracking how Baltimore invests settlement dollars from opioid litigation into harm reduction, treatment, and community services.
State Senator Pat McMath proposes using unspent opioid settlement dollars to fund clinical research into psychedelic-assisted therapy for veterans, first responders, and people with opioid dependence.